Evidence map›Paper›PMID 42510436›Full record

ArticleBioengineering (Basel, Switzerland)2026

Scalable Isolation of Human Umbilical Cord MSC-Derived Exosomes and Their Therapeutic Potential in Osteoarthritis.

Chao Zhou, Shimei Wu, Yanyi Zeng, Xueyan Liu, Shiye Wu, Ke Chen, Junrong Wu, Haibin Yin, Yuanyuan Zhou

Abstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chao ZhouSchool of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, 66 Gongchanglu Road, Guangming District, Shenzhen 518107, China.
Shimei WuGuangzhou Anjie Biomedical Technology Co., Ltd., Guangzhou 510005, China.
Yanyi ZengSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Xueyan LiuGuangzhou Anjie Biomedical Technology Co., Ltd., Guangzhou 510005, China.
Shiye WuSchool of Animal Science and Technology, Foshan University, Foshan 528225, China.
Ke ChenSchool of Animal Science and Technology, Foshan University, Foshan 528225, China.
Junrong WuGuangzhou Anjie Biomedical Technology Co., Ltd., Guangzhou 510005, China.
Haibin YinGuangzhou Anjie Biomedical Technology Co., Ltd., Guangzhou 510005, China.
Yuanyuan ZhouSchool of Agriculture and Bioengineering, Foshan University, Foshan 528225, China.ORCID 0000-0002-3684-6126

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA) is a prevalent degenerative joint disorder characterized by cartilage degradation, synovial inflammation, and osteophyte formation, yet effective therapies that alter disease progression remain absent. Mesenchymal stem cell-derived exosomes (MSC-EXOs), as a cell-free regenerative medicine strategy, have shown great potential in the treatment of osteoarthritis. In this study, we successfully isolated and purified exosomes derived from human umbilical cord mesenchymal stem cells using a scalable tangential flow filtration (TFF)-chromatography platform and evaluated their therapeutic effects on OA model induced by anterior cruciate ligament transection (ACLT). OARSI scores were significantly reduced compared with the ACLT group (

Indexed as

cartilage repairexosomeshuman umbilical cord MSCsinflammationosteoarthritis

Identifiers

PMID42510436
PMCPMC13404446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.